We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+6.27%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.02B
AUM Growth
-$45.6M
Cap. Flow
-$64.3M
Cap. Flow %
-6.32%
Top 10 Hldgs %
45.69%
Holding
126
New
39
Increased
20
Reduced
28
Closed
30

Top Buys

Rank Stock Value
1
BTAI icon
BioXcel Therapeutics
BTAI
+$12.6M
2
JNJ icon
Johnson & Johnson
JNJ
+$11.8M
3
GNRC icon
Generac Holdings
GNRC
+$11M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$10.6M
5
LLY icon
Eli Lilly
LLY
+$10.2M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$41.2M
2
NVO
Novo Nordisk
NVO
+$26.2M
3
NICE icon
Nice
NICE
+$14.2M
4
FVRR icon
Fiverr
FVRR
+$11.8M
5
QTTB icon
Q32 Bio
QTTB
+$10M

Sector Composition

Rank Sector Weight
1 Healthcare 70.42%
2 Technology 5.67%
3 Consumer Discretionary 2.57%
4 Industrials 2.19%
5 Communication Services 1.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CPRX
101
DELISTED
Catalyst Pharmaceutical
CPRX
– –
-730,557
Closed -$3.38M
DOV icon
102
Dover
DOV
$27.6B
– –
-57,576
Closed -$5.56M
ENPH icon
103
Enphase Energy
ENPH
$4.96B
– –
-70,000
Closed -$3.33M
IMUX icon
104
Immunic
IMUX
$190M
– –
-10,000
Closed -$1.21M
KPTI icon
105
Karyopharm Therapeutics
KPTI
$43.5M
– –
-26,189
Closed -$7.44M
LITS
106
Lite Strategy Inc
LITS
$32.8M
– –
-20,500
Closed -$1.69M
NVO
107
Novo Nordisk
NVO
$208B
– –
-800,000
Closed -$26.2M
PANW icon
108
Palo Alto Networks
PANW
$270B
– –
-180,000
Closed -$6.89M
PFE icon
109
PUT
Pfizer
PFE
$143B
– –
-1,054,000
Closed -$32.7M
SLNO
110
DELISTED
Soleno Therapeutics
SLNO
– –
-82,245
Closed -$2.74M
SNDX icon
111
CALL
Syndax Pharmaceuticals
SNDX
$1.69B
– –
-100,000
Closed -$1.48M
SPY icon
112
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$790B
– –
-189,000
Closed -$58.3M
TVTX icon
113
Travere Therapeutics
TVTX
$5.2B
– –
-250,000
Closed -$5.1M
VKTX icon
114
Viking Therapeutics
VKTX
$3.7B
– –
-205,000
Closed -$1.48M
WIX icon
115
WIX.com
WIX
$2.3B
– –
-37,588
Closed -$9.63M
XBI icon
116
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.95B
– –
-750,000
Closed -$84M
XFOR icon
117
X4 Pharmaceuticals
XFOR
$375M
– –
-18,860
Closed -$5.27M
QTTB icon
118
Q32 Bio
QTTB
$466M
– –
-36,607
Closed -$10M
ITCI
119
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-228,700
Closed -$5.87M
ISEE
120
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-200,000
Closed -$1.02M
BLU
121
DELISTED
BELLUS Health Inc.
BLU
– –
-97,805
Closed -$1.01M
TCRR
122
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
– –
-30,000
Closed -$461K
AKUS
123
DELISTED
Akouos Inc
AKUS
– –
-100,000
Closed -$2.25M
NEOS
124
DELISTED
Neos Therapeutics, Inc
NEOS
– –
-950,311
Closed -$651K
ARYAU
125
DELISTED
ARYA Sciences Acquisiton Corp. Unit
ARYAU
– –
-200,000
Closed -$4M
1 2 3 4
5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q3 2020 Portfolio in Review

As of Q3 2020, Sphera Funds Management held 126 positions worth $1.02B, down 4.3% from $1.06B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Sphera Funds Management withdrew a net $64.3M in Q3 2020, closing 30 positions and reducing 28 holdings. Its most notable exit was Bristol-Myers Squibb, an estimated $41.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 64% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Sphera Funds Management opened a new position in BioXcel Therapeutics worth $11.7M.

  • Sphera Funds Management's largest Q3 2020 buy was BioXcel Therapeutics: 16,831 shares worth $11.7M.
  • Sphera Funds Management added most to Johnson & Johnson in Q3 2020, an estimated $11.8M increase.
  • Sphera Funds Management's biggest Q3 2020 reduction was Nice, cutting an estimated $14.2M.
  • Sphera Funds Management fully exited Bristol-Myers Squibb in Q3 2020, selling an estimated $41.2M.
  • Sphera Funds Management's ten largest holdings make up 46% of its $1.02B portfolio in Q3 2020.
  • Sphera Funds Management opened 39 new positions and closed 30 in Q3 2020.
  • Sphera Funds Management's portfolio value fell 4.3% quarter-over-quarter to $1.02B.

Based on Sphera Funds Management's 13F filing for Q3 2020, filed 12 Nov 2020.